The vitreous body changes through collagen metabolism, so that a nutritive influence here is plausible.
Can a relatively short-term diet bring change to those already affected?
To answer this important question scientifically, there have been studies in the recent past. Five clinical examinations 1,2,3,4,5 confirmed the success rate of relief in 65-85% of the patients after 3-6 months of supplementation of special micronutrients and confirmed it several times.
Some results and investigations are briefly described below:
In a case study of 463 patients with vitreous floaters, the success rate was of over 60% with oral suplementation of special micronutrients.
(Scale from 0-4; no disturbance – extreme disturbance)
3 months 1 capsule per day with L-lysine (125mg), hesperidin (60mg), citrus flavonoids (23.75mg), vitamin C (40mg) and zinc (5mg);
Little improvement 25,9 %
Moderate improvement 27,6 %
Significant improvement 28,4 % / 64,7 %
Drastic improvement 8,7 % / 90,6 %
1) Sobol M., Oseka M., Kaercher Th., Schmiedchen B.. Journal of Alzheimer`s Disease 64 (2018), BON conference Abstracts (BON 030), S. 16-17
In 2013, a data collection for the daily intake of VitroCap® capsules over a period of 12 weeks, has been conducted in the ophthalmological practice of Dr.Th. Kaercher, Heidelberg.
24 patients (no control group) were included in the observation. The age range of the patients was 21-81 years. The subjective symptoms were quantified in 5 levels (1- low 5- and extreme discomfort), describing the strength of the perceived interference. In
addition, the patients were questioned about when the disturbances were most apparent. At the end of the supplementation period, the extent of the improvement was documented.
Over 80% of the participants reported that the disturbances in the field of vision were particularly noticed in the morning, in the evening and while reading. The number of adverse effects after intake was reduced significantly at all times.
In assessing whether the symptoms improved after the supplementation with VitroCap®, it was affirmed by 21 patients.
Fig.1) Interference by “floaters”. Average score before (orange) and after VitroCap®-taking on a scale of 1 – 5 results (1 = poor, 5 = extremely)
1.) Gerste RD, Kaercher Th, Pharma_Report, ZPA 344; April 2013
(n = 24)
The level of interference was reduced considerably. Fig.1